Evidence map›Paper›PMID 37646983›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2024

Palliative care for children with central nervous system tumors: results of a Spanish multicenter study.

Maria Pérez-Torres Lobato, Lucía Navarro-Marchena, Iñigo de Noriega, Miriam Morey Olivé, Palma Solano-Páez, Eloísa Rubio Pérez, Carmen Garrido Colino, Miriam García Abos, María Tallón García, Beatriz Huidobro Labarga and 11 more

Open access · hybridAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 2 countries.

Maria Pérez-Torres LobatoDivision of Pediatric Hematology and Oncology, Vall d'Hebrón Hospital, Pg. de La Vall d'Hebron, 119, 08035, Barcelona, Spain.
Lucía Navarro-MarchenaPalliative Care and Complex Chronic Patient Service, Sant Joan de Déu Hospital, Barcelona, Spain.
Iñigo de NoriegaPediatric Palliative Care Unit, Niño Jesús Hospital, Madrid, Spain.
Miriam Morey OlivéDivision of General Pediatrics, Vall d'Hebrón Hospital, Barcelona, Spain.
Palma Solano-PáezPediatric Oncology Unit, Virgen del Rocio Hospital, Seville, Spain.
Eloísa Rubio PérezMethodological and Statistical Management Unit, FISEVI, Virgen del Rocio Hospital, Seville, Spain.
Carmen Garrido ColinoPediatric Oncology Unit, Gregorio Marañon Hospital, Madrid, Spain.
Miriam García AbosPediatric Oncology Unit, Donostia University Hospital, Donostia, Spain.
María Tallón GarcíaPediatric Oncology Unit, Álvaro Cunqueiro Hospital, Vigo, Spain.
Beatriz Huidobro LabargaPalliative Care Unit, Virgen de La Salud Hospital, Toledo, Spain.
Raquel Portugal RodríguezPediatric Oncology Unit, Burgos University Hospital, Burgos, Spain.
Blanca López IborPediatric Oncology Unit, Montepríncipe Hospital, Madrid, Spain.
Álvaro LassalettaDivision of Pediatric Hematology and Oncology, Niño Jesús Hospital, Madrid, Spain.
Andrés Morgenstern IsaakPediatric Palliative Care Unit, Vall d'Hebrón Hospital, Barcelona, Spain.
Ofelia Cruz MartínezDivision of Pediatric Hematology and Oncology, Pediatric Cancer Center Barcelona, Barcelona, Spain.
Lorena Valero ArreseDivision of Pediatric Hematology and Oncology, Vall d'Hebrón Hospital, Pg. de La Vall d'Hebron, 119, 08035, Barcelona, Spain.
Anna Llort SalesDivision of Pediatric Hematology and Oncology, Vall d'Hebrón Hospital, Pg. de La Vall d'Hebron, 119, 08035, Barcelona, Spain.
Luis Gros SubiasDivision of Pediatric Hematology and Oncology, Vall d'Hebrón Hospital, Pg. de La Vall d'Hebron, 119, 08035, Barcelona, Spain.
Catalina Márquez VegaPediatric Oncology Unit, Virgen del Rocio Hospital, Seville, Spain.
Lucas MorenoDivision of Pediatric Hematology and Oncology, Vall d'Hebrón Hospital, Pg. de La Vall d'Hebron, 119, 08035, Barcelona, Spain. lucas.moreno@vallhebron.cat.ORCID http://orcid.org/0000-0002-0708-1670
Eduardo Quiroga-CanteroPediatric Oncology Unit, Virgen del Rocio Hospital, Seville, Spain.
Hebron University · PSHospital Universitario Virgen del Rocío · ESHospital Infantil Universitario Niño Jesús · ESVall d'Hebron Hospital Universitari · ESBiogipuzkoa Health Research Institute · ESFundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla · ESHospital General Universitario Gregorio Marañón · ESHospital Sant Joan de Déu Barcelona · ESHospital Virgen de la Salud · ESUniversity Hospital Complex Of Vigo · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBrain tumors represent the most common cause of cancer-related death in children. Few studies concerning the palliative phase in children with brain tumors are available.

objectives(i) To describe the palliative phase in children with brain tumors; (ii) to determine whether the use of palliative sedation (PS) depends on the place of death, the age of the patient, or if they received specific palliative care (PC).

methodsRetrospective multicenter study between 2010 and 2021, including children from one month to 18 years, who had died of a brain tumor.

results228 patients (59.2% male) from 10 Spanish institutions were included. Median age at diagnosis was 5 years (IQR 2-9) and median age at death was 7 years (IQR 4-11). The most frequent tumors were medulloblastoma (25.4%) and diffuse intrinsic pontine glioma (DIPG) (24.1%). Median number of antineoplastic regimens were 2 (range 0-5 regimens). During palliative phase, 52.2% of the patients were attended by PC teams, while 47.8% were cared exclusively by pediatric oncology teams. Most common concerns included motor deficit (93.4%) and asthenia (87.5%) and communication disorders (89.8%). Most frequently prescribed supportive drugs were antiemetics (83.6%), opioids (81.6%), and dexamethasone (78.5%). PS was administered to 48.7% patients. Most of them died in the hospital (85.6%), while patients who died at home required PS less frequently (14.4%) (p = .01).

conclusionChildren dying from CNS tumors have specific needs during palliative phase. The optimal indication of PS depended on the center experience although, in our series, it was also influenced by the place of death.

Indexed as

Brain NeoplasmsCentral Nervous System NeoplasmsCerebellar NeoplasmsMedulloblastomaNeoplasmsTerminal CareChildChild, PreschoolFemaleHumansMalePalliative CareRetrospective StudiesBrain tumorChildhood cancerCNS tumorEnd-of-lifeNeuro-oncologyPalliative

Identifiers

PMID37646983
OpenAlexW4386272255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.